Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.78 |
| ▸ | KIT | P10721 | 17/20 | 0.78 |
| ▸ | ABL2 | P42684 | 13/20 | 0.78 |
| ▸ | BCR | P11274 | 8/20 | 0.78 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.78 |
| ▸ | PLK4 | O00444 | 1/20 | 0.78 |
| ▸ | DDX3X | O00571 | 1/20 | 0.78 |
| ▸ | GAK | O14976 | 1/20 | 0.78 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.78 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.78 |
| ▸ | CA12 | O43570 | 1/20 | 0.78 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | EGFR | P00533 | 1/20 | 0.78 |
| ▸ | CA1 | P00915 | 1/20 | 0.78 |
| ▸ | CA2 | P00918 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | ALB | P02768 | 1/20 | 0.78 |
| ▸ | RAF1 | P04049 | 1/20 | 0.78 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30752396 | 1.00 | ABL1 (0.78) | ABL1KITABL2BCRPDGFRA | |
| SCHEMBL18210973 | 0.91 | ABL1 (0.78) | ABL1KITABL2BCRPDGFRA | |
| SCHEMBL13437239 | 0.90 | ABL1 (0.87) | ABL1KITABL2BCRPDGFRA | |
| SCHEMBL3040065 | 0.88 | PDGFRA (0.75) | ABL1KITABL2BCRPDGFRA | |
| SCHEMBL5202204 | 0.88 | ABL1 (0.59) | ABL1KITABL2BCRPDGFRA | |
| Imatinib SCHEMBL2236091 | 0.88 | ABL1 (1.00) | ABL1KITABL2BCRPDGFRA | |
| Imatinib SCHEMBL29355523 | 0.88 | ABL1 (1.00) | ABL1KITABL2BCRPDGFRA | |
| Imatinib SCHEMBL29351601 | 0.88 | ABL1 (1.00) | ABL1KITABL2BCRPDGFRA | |
| Imatinib SCHEMBL3827 | 0.88 | ABL1 (1.00) | ABL1KITABL2BCRPDGFRA | |
| Imatinib SCHEMBL529425 | 0.87 | ABL1 (0.98) | ABL1KITABL2BCRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194049-B1 | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2014-08-13 | — | — | EP | claimed |
| EP-2194049-A1 | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | Novartis AG (CH) | 2010-06-09 | — | — | EP | claimed |
| US-20050209452-A1 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2005-09-22 | — | — | US | claimed |
| US-20140323494-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | disclosed |
| EP-2194049-B1 | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-20110294820-A1 | N-Oxides of n-Phenyl-2-pyrimidine-amine Derivatives | BOERNSEN KLAUS OLAF (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20100222362-A1 | N-OXIDES OF N-PHENYL-2-PYRAMIDINE-AMINE DERIVATIVES | BOERNSEN KLAUS OLAF | 2010-09-02 | — | — | US | disclosed |
| EP-2194049-A1 | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | Novartis AG (CH) | 2010-06-09 | — | — | EP | disclosed |
| US-20090239879-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | BORNSEN KLAUS OLAF | 2009-09-24 | — | — | US | disclosed |
| US-7557105-B2 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2009-07-07 | — | — | US | disclosed |
| EP-1783126-A2 | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | Novartis AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| US-20050209452-A1 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222362-A1 | N-OXIDES OF N-PHENYL-2-PYRAMIDINE-AMINE DERIVATIVES | NUDT1, NT5C2, NOX5 | ABL1 162/4885KIT 2236/4885ABL2 128/4885 |
| US-20110294820-A1 | N-Oxides of n-Phenyl-2-pyrimidine-amine Derivatives | NUDT1, PNP, NME2 | ABL1 106/4885KIT 2044/4885ABL2 164/4885 |
| US-20050209452-A1 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | MKI67, CDK4, NME2 | ABL1 19/4885KIT 505/4885ABL2 92/4885 |
| US-20140323494-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NUDT1, PNP, NME2 | ABL1 104/4885KIT 1974/4885ABL2 143/4885 |
| US-20090239879-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NUDT1, PNP, NME2 | ABL1 106/4885KIT 2044/4885ABL2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.